Annelien Duits

Dr. Annelien Duits

Department of Medical Psychology, Maastricht University Medical Center; Department of Psychiatry and Neuropsychology Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
AWAmée F. Wolters
Amée F. Wolters
SWSjors C.F. van de Weijer
Sjors C.F. van de Weijer
ALAlbert Leentjens
Albert Leentjens
ADAnnelien Duits
Annelien Duits
Heidi I.L. JacobsHeidi I.L. Jacobs
Heidi I.L. Jacobs
MKMark L. Kuijf
Mark L. Kuijf

7 November 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
JHJoshua Harvey
Joshua Harvey
RRRick A. Reijnders
Rick A. Reijnders
RCRachel Cavill
Rachel Cavill
ADAnnelien Duits
Annelien Duits
SKSebastian Köhler
Sebastian Köhler
EPEhsan Pishva
Ehsan Pishva
Cognitive impairment is a debilitating symptom in Parkinson’s disease (PD). We aimed to establish an accurate multivariate machine learning (ML) model to predict cognitive outcome in newly diagnosed PD cases from the Parkinson’s Progression Markers Initiative (PPMI). Annual cognitive assessments over an 8-year time span were used to define two cognitive outcomes of (i) cognitive impairment, and (ii) dementia conversion. Selected baseline variables were organized into three subsets of clinical, biofluid and genetic/epigenetic measures and tested using four different ML algorithms. Irrespective of the ML algorithm used, the models consisting of the clinical variables performed best and showed better prediction of cognitive impairment outcome over dementia conversion. We observed a marginal improvement in the prediction performance when clinical, biofluid, and epigenetic/genetic variables were all included in one model. Several cerebrospinal fluid measures and an epigenetic marker showed high predictive weighting in multiple models when included alongside clinical variables.

1 March 2022 in Resuscitation
Verified
Journal Article
Open access
PGPauline van Gils
Pauline van Gils
CHCaroline van Heugten
Caroline van Heugten
JHJeannette Hofmeijer
Jeannette Hofmeijer
HKHanneke Keijzer
Hanneke Keijzer
SNSjoukje Nutma
Sjoukje Nutma
ADAnnelien Duits
Annelien Duits
The survival rate of out-of-hospital cardiac arrest (OHCA) patients has increased over the past decades. This gives rise to a growing number of patients with hypoxic-ischemic brain damage and cognitive impairment. Currently, cognitive impairment is underdiagnosed in OHCA patients. There is a need for a validated cognitive screening instrument to identify patients with cognitive impairment. This study aimed to examine the diagnostic value of the Montreal Cognitive Assessment (MoCA) in patients after OHCA. Survivors (age ≥ 18 years) of OHCA completed the MoCA and a gold standard neuropsychological test battery, including tests for memory, attention, perception, language, reasoning, and executive functioning, at around one year after OHCA. Results of the MoCA are related to the results of the neuropsychological test battery. Analyses of diagnostic accuracy included receiver operating characteristics and calculation of predictive values. We included 54 OHCA survivors (mean age = 57.3, 74% male). The area under the curve (AUC) was 0.8, 95% CI [0.67, 0.93]. The MoCA showed excellent sensitivity of 86%, 95% CI [57, 98] and adequate specificity of 70.0%, 95% CI [53, 83] to detect cognitive impairment at the regular cut-off score of 26. The positive predictive value of the MoCA was 50%, 95% CI [30, 70] and the negative predictive value was 93%, 95% CI [76, 99]. This study shows that the MoCA may be a valid cognitive screening instrument for use in the OHCA patient population.

24 May 2012 in European Child & Adolescent Psychiatry
Verified
Journal Article
Open access
PDF file
ADAnnelien Duits
Annelien Duits
LAL. Ackermans
L. Ackermans
DCD. Cath
D. Cath
VVV. Visser-Vandewalle
V. Visser-Vandewalle

27 March 2025 in Movement Disorders
Verified
Journal Article
Open access
OBOndrej Bezdicek
Ondrej Bezdicek
RBRoberta Biundo
Roberta Biundo
SBSarai Boelema
Sarai Boelema
DCDavide Maria Cammisuli
Davide Maria Cammisuli
BCBrenna Cholerton
Brenna Cholerton
TCthe members of the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee
the members of the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee
Background: Cognitive impairment in Parkinson's disease (PD) is a key non‐motor complication during the disease course.Objectives: A review of detailed cognitive instruments to detect mild cognitive impairment (PD‐MCI) or dementia (PDD) is needed to establish optimal tests that facilitate diagnostic accuracy.Methods: We performed a systematic literature review of tests that assess memory, language including premorbid intelligence, and visuospatial domains (for tests of attention and executive functions see accompanying review) to determine suitability to assess cognition in PD. Based on in‐depth scrutiny of psychometric and other relevant clinimetric properties, tests were rated as “recommended,” “recommended with caveats,” “suggested,” or “listed” by the International Parkinson and Movement Disorder Society (IPMDS) panel of experts according to the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee guidelines.Results: We included 39 tests encompassing 48 outcome measures. Seven tests (different versions or subtests of the test counted once) were recommended, including four for memory, one for visuospatial domains, one for language (including three measures), and one for estimated premorbid intelligence. Furthermore, 10 tests (12 measures) were “recommended with caveats,” 11 were “suggested,” and 11 (15 measures) were “listed.”Conclusions: Recommended neuropsychological tests in memory, visuospatial functions, and language are proposed to guide the assessment of cognitive impairment and its progression in PD‐MCI and PDD, and for use in clinical trials to stratify participants or as outcome measures. Novel measures being developed will need extensive validation research to be “recommended.” © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

1 January 2021 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Open access
AMAnne E.P. Mulders
Anne E.P. Mulders
Yasin TemelYasin Temel
Yasin Temel
MTMehmet Tonge
Mehmet Tonge
FSFrédéric L.W.V.J. Schaper
Frédéric L.W.V.J. Schaper
VKVivianne van Kranen-Mastenbroek
Vivianne van Kranen-Mastenbroek
ADAnnelien Duits
Annelien Duits
Despite optimal improvement in motor functioning, both short- and long-term studies have reported small but consistent changes in cognitive functioning following STN-DBS in Parkinson's disease (PD). The aim of the present study was to explore whether surgical characteristics were associated with cognitive decline one year following STN-DBS. We retrospectively analyzed 49 PD patients who underwent bilateral STN-DBS. Cognitive change scores were related to the number of microelectrode recording (MER) trajectories, the STN length as measured by MER, and cortical entry points. Regression analyses were corrected for age at surgery, disease duration, education and preoperative levodopa responsiveness. Patients were then divided into a cognitive and non-cognitive decline group for each neuropsychological test and compared regarding demographic and surgical characteristics. One year postoperatively, significant declines were found in verbal fluency, Stroop Color-Word test and Trail Making Test B (TMT-B). Only changes in TMT-B were associated with the coronal entry point in the right hemisphere. The number of MER trajectories and STN length were not associated with cognitive change scores. When comparing the cognitive decline and non-cognitive decline groups, no significant differences were found in surgical characteristics. The electrode passage through the right prefrontal lobe may contribute to subtle changes in executive function. However, only few patients showed clinically relevant cognitive decline. The use of multiple MER trajectories and a longer STN length were not associated with cognitive decline one year following surgery. From a cognitive point of view, DBS may be considered a relatively safe procedure.